{"entity":{"id":"io102-io103","kind":"drug","name":"IO102-IO103","aka":[],"tldr":"IO102-IO103 is an experimental peptide (immunotherapeutic vaccine) from IO Biotech in phase 3 trials for melanoma and head and neck squamous cell carcinoma, aimed at PD-L1.","summary":"IO102-IO103 (IO102, IO103) is a peptide (immunotherapeutic vaccine) developed by IO Biotech. Its target is PD-L1 (the sponsor names IDO1 and PD-L1). The sponsor states: IO102-IO103 comprises an IDO peptide antigen (IO102) and a PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) and given subcutaneously to stimulate an immune response against IDO- and PD-L1-expressing cells, dosed alongside pembrolizumab in advanced melanoma. ClinicalTrials.gov describes the intervention as: IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05155254 (IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)), in melanoma and head and neck squamous cell carcinoma. The largest, NCT05155254, plans to enrol 407 participants (actual) with primary completion was scheduled for 2025-05-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of IO102-IO103","url":"https://clinicaltrials.gov/search?intr=IO102"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","head-and-neck"],"sections":[],"technologies":[],"targets":["pdl1","ido1"],"drugs":[],"companies":["io-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05155254","nct05280314"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"IO102, IO103","modality":"peptide (immunotherapeutic vaccine)","mechanism":"IO102-IO103 comprises an IDO peptide antigen (IO102) and a PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) and given subcutaneously to stimulate an immune response against IDO- and PD-L1-expressing cells, dosed alongside pembrolizumab in advanced melanoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/io102-io103/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"ido1","kind":"target","name":"IDO1","route":"/targets/ido1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/"}],"trial":[{"id":"nct05155254","kind":"trial","name":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","route":"/trials/nct05155254/"},{"id":"nct05280314","kind":"trial","name":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","route":"/trials/nct05280314/"}]}}